- •Hematuria II: causes and investigation
- •Hematospermia
- •Lower urinary tract symptoms (LUTS)
- •Nocturia and nocturnal polyuria
- •Flank pain
- •Urinary incontinence in adults
- •Genital symptoms
- •Abdominal examination in urological disease
- •Digital rectal examination (DRE)
- •Lumps in the groin
- •Lumps in the scrotum
- •2 Urological investigations
- •Urine examination
- •Urine cytology
- •Radiological imaging of the urinary tract
- •Uses of plain abdominal radiography (KUB X-ray—kidneys, ureters, bladder)
- •Intravenous pyelography (IVP)
- •Other urological contrast studies
- •Computed tomography (CT) and magnetic resonance imaging (MRI)
- •Radioisotope imaging
- •Post-void residual urine volume measurement
- •3 Bladder outlet obstruction
- •Regulation of prostate growth and development of benign prostatic hyperplasia (BPH)
- •Pathophysiology and causes of bladder outlet obstruction (BOO) and BPH
- •Benign prostatic obstruction (BPO): symptoms and signs
- •Diagnostic tests in men with LUTS thought to be due to BPH
- •Why do men seek treatment for their symptoms?
- •Watchful waiting for uncomplicated BPH
- •Medical management of BPH: combination therapy
- •Medical management of BPH: alternative drug therapy
- •Minimally invasive management of BPH: surgical alternatives to TURP
- •Invasive surgical alternatives to TURP
- •TURP and open prostatectomy
- •Indications for and technique of urethral catheterization
- •Indications for and technique of suprapubic catheterization
- •Management of nocturia and nocturnal polyuria
- •High-pressure chronic retention (HPCR)
- •Bladder outlet obstruction and retention in women
- •Urethral stricture disease
- •4 Incontinence
- •Causes and pathophysiology
- •Evaluation
- •Treatment of sphincter weakness incontinence: injection therapy
- •Treatment of sphincter weakness incontinence: retropubic suspension
- •Treatment of sphincter weakness incontinence: pubovaginal slings
- •Overactive bladder: conventional treatment
- •Overactive bladder: options for failed conventional therapy
- •“Mixed” incontinence
- •Post-prostatectomy incontinence
- •Incontinence in the elderly patient
- •Urinary tract infection: microbiology
- •Lower urinary tract infection
- •Recurrent urinary tract infection
- •Urinary tract infection: treatment
- •Acute pyelonephritis
- •Pyonephrosis and perinephric abscess
- •Other forms of pyelonephritis
- •Chronic pyelonephritis
- •Septicemia and urosepsis
- •Fournier gangrene
- •Epididymitis and orchitis
- •Periurethral abscess
- •Prostatitis: presentation, evaluation, and treatment
- •Other prostate infections
- •Interstitial cystitis
- •Tuberculosis
- •Parasitic infections
- •HIV in urological surgery
- •6 Urological neoplasia
- •Pathology and molecular biology
- •Prostate cancer: epidemiology and etiology
- •Prostate cancer: incidence, prevalence, and mortality
- •Prostate cancer pathology: premalignant lesions
- •Counseling before prostate cancer screening
- •Prostate cancer: clinical presentation
- •PSA and prostate cancer
- •PSA derivatives: free-to-total ratio, density, and velocity
- •Prostate cancer: transrectal ultrasonography and biopsies
- •Prostate cancer staging
- •Prostate cancer grading
- •General principles of management of localized prostate cancer
- •Management of localized prostate cancer: watchful waiting and active surveillance
- •Management of localized prostate cancer: radical prostatectomy
- •Postoperative course after radical prostatectomy
- •Prostate cancer control with radical prostatectomy
- •Management of localized prostate cancer: radical external beam radiotherapy (EBRT)
- •Management of localized prostate cancer: brachytherapy (BT)
- •Management of localized and radiorecurrent prostate cancer: cryotherapy and HIFU
- •Management of locally advanced nonmetastatic prostate cancer (T3–4 N0M0)
- •Management of advanced prostate cancer: hormone therapy I
- •Management of advanced prostate cancer: hormone therapy II
- •Management of advanced prostate cancer: hormone therapy III
- •Management of advanced prostate cancer: androgen-independent/ castration-resistant disease
- •Palliative management of prostate cancer
- •Prostate cancer: prevention; complementary and alternative therapies
- •Bladder cancer: epidemiology and etiology
- •Bladder cancer: pathology and staging
- •Bladder cancer: presentation
- •Bladder cancer: diagnosis and staging
- •Muscle-invasive bladder cancer: surgical management of localized (pT2/3a) disease
- •Muscle-invasive bladder cancer: radical and palliative radiotherapy
- •Muscle-invasive bladder cancer: management of locally advanced and metastatic disease
- •Bladder cancer: urinary diversion after cystectomy
- •Transitional cell carcinoma (UC) of the renal pelvis and ureter
- •Radiological assessment of renal masses
- •Benign renal masses
- •Renal cell carcinoma: epidemiology and etiology
- •Renal cell carcinoma: pathology, staging, and prognosis
- •Renal cell carcinoma: presentation and investigations
- •Renal cell carcinoma: active surveillance
- •Renal cell carcinoma: surgical treatment I
- •Renal cell carcinoma: surgical treatment II
- •Renal cell carcinoma: management of metastatic disease
- •Testicular cancer: epidemiology and etiology
- •Testicular cancer: clinical presentation
- •Testicular cancer: serum markers
- •Testicular cancer: pathology and staging
- •Testicular cancer: prognostic staging system for metastatic germ cell cancer
- •Testicular cancer: management of non-seminomatous germ cell tumors (NSGCT)
- •Testicular cancer: management of seminoma, IGCN, and lymphoma
- •Penile neoplasia: benign, viral-related, and premalignant lesions
- •Penile cancer: epidemiology, risk factors, and pathology
- •Squamous cell carcinoma of the penis: clinical management
- •Carcinoma of the scrotum
- •Tumors of the testicular adnexa
- •Urethral cancer
- •Wilms tumor and neuroblastoma
- •7 Miscellaneous urological diseases of the kidney
- •Cystic renal disease: simple cysts
- •Cystic renal disease: calyceal diverticulum
- •Cystic renal disease: medullary sponge kidney (MSK)
- •Acquired renal cystic disease (ARCD)
- •Autosomal dominant (adult) polycystic kidney disease (ADPKD)
- •Ureteropelvic junction (UPJ) obstruction in adults
- •Anomalies of renal ascent and fusion: horseshoe kidney, pelvic kidney, malrotation
- •Renal duplications
- •8 Stone disease
- •Kidney stones: epidemiology
- •Kidney stones: types and predisposing factors
- •Kidney stones: mechanisms of formation
- •Evaluation of the stone former
- •Kidney stones: presentation and diagnosis
- •Kidney stone treatment options: watchful waiting
- •Stone fragmentation techniques: extracorporeal lithotripsy (ESWL)
- •Intracorporeal techniques of stone fragmentation (fragmentation within the body)
- •Kidney stone treatment: percutaneous nephrolithotomy (PCNL)
- •Kidney stones: open stone surgery
- •Kidney stones: medical therapy (dissolution therapy)
- •Ureteric stones: presentation
- •Ureteric stones: diagnostic radiological imaging
- •Ureteric stones: acute management
- •Ureteric stones: indications for intervention to relieve obstruction and/or remove the stone
- •Ureteric stone treatment
- •Treatment options for ureteric stones
- •Prevention of calcium oxalate stone formation
- •Bladder stones
- •Management of ureteric stones in pregnancy
- •Hydronephrosis
- •Management of ureteric strictures (other than UPJ obstruction)
- •Pathophysiology of urinary tract obstruction
- •Ureter innervation
- •10 Trauma to the urinary tract and other urological emergencies
- •Renal trauma: clinical and radiological assessment
- •Renal trauma: treatment
- •Ureteral injuries: mechanisms and diagnosis
- •Ureteral injuries: management
- •Bladder and urethral injuries associated with pelvic fractures
- •Bladder injuries
- •Posterior urethral injuries in males and urethral injuries in females
- •Anterior urethral injuries
- •Testicular injuries
- •Penile injuries
- •Torsion of the testis and testicular appendages
- •Paraphimosis
- •Malignant ureteral obstruction
- •Spinal cord and cauda equina compression
- •11 Infertility
- •Male reproductive physiology
- •Etiology and evaluation of male infertility
- •Lab investigation of male infertility
- •Oligospermia and azoospermia
- •Varicocele
- •Treatment options for male factor infertility
- •12 Disorders of erectile function, ejaculation, and seminal vesicles
- •Physiology of erection and ejaculation
- •Impotence: evaluation
- •Impotence: treatment
- •Retrograde ejaculation
- •Peyronie’s disease
- •Priapism
- •13 Neuropathic bladder
- •Innervation of the lower urinary tract (LUT)
- •Physiology of urine storage and micturition
- •Bladder and sphincter behavior in the patient with neurological disease
- •The neuropathic lower urinary tract: clinical consequences of storage and emptying problems
- •Bladder management techniques for the neuropathic patient
- •Catheters and sheaths and the neuropathic patient
- •Management of incontinence in the neuropathic patient
- •Management of recurrent urinary tract infections (UTIs) in the neuropathic patient
- •Management of hydronephrosis in the neuropathic patient
- •Bladder dysfunction in multiple sclerosis, in Parkinson disease, after stroke, and in other neurological disease
- •Neuromodulation in lower urinary tract dysfunction
- •14 Urological problems in pregnancy
- •Physiological and anatomical changes in the urinary tract
- •Urinary tract infection (UTI)
- •Hydronephrosis
- •15 Pediatric urology
- •Embryology: urinary tract
- •Undescended testes
- •Urinary tract infection (UTI)
- •Ectopic ureter
- •Ureterocele
- •Ureteropelvic junction (UPJ) obstruction
- •Hypospadias
- •Normal sexual differentiation
- •Abnormal sexual differentiation
- •Cystic kidney disease
- •Exstrophy
- •Epispadias
- •Posterior urethral valves
- •Non-neurogenic voiding dysfunction
- •Nocturnal enuresis
- •16 Urological surgery and equipment
- •Preparation of the patient for urological surgery
- •Antibiotic prophylaxis in urological surgery
- •Complications of surgery in general: DVT and PE
- •Fluid balance and management of shock in the surgical patient
- •Patient safety in the operating room
- •Transurethral resection (TUR) syndrome
- •Catheters and drains in urological surgery
- •Guide wires
- •JJ stents
- •Lasers in urological surgery
- •Diathermy
- •Sterilization of urological equipment
- •Telescopes and light sources in urological endoscopy
- •Consent: general principles
- •Cystoscopy
- •Transurethral resection of the prostate (TURP)
- •Transurethral resection of bladder tumor (TURBT)
- •Optical urethrotomy
- •Circumcision
- •Hydrocele and epididymal cyst removal
- •Nesbit procedure
- •Vasectomy and vasovasostomy
- •Orchiectomy
- •Urological incisions
- •JJ stent insertion
- •Nephrectomy and nephroureterectomy
- •Radical prostatectomy
- •Radical cystectomy
- •Ileal conduit
- •Percutaneous nephrolithotomy (PCNL)
- •Ureteroscopes and ureteroscopy
- •Pyeloplasty
- •Laparoscopic surgery
- •Endoscopic cystolitholapaxy and (open) cystolithotomy
- •Scrotal exploration for torsion and orchiopexy
- •17 Basic science of relevance to urological practice
- •Physiology of bladder and urethra
- •Renal anatomy: renal blood flow and renal function
- •Renal physiology: regulation of water balance
- •Renal physiology: regulation of sodium and potassium excretion
- •Renal physiology: acid–base balance
- •18 Urological eponyms
- •Index
Chapter 14 |
531 |
|
|
Urological problems in pregnancy
Physiological and anatomical changes in the urinary tract 532 Urinary tract infection (UTI) 534
Hydronephrosis 536
532 CHAPTER 14 Urological problems in pregnancy
Physiological and anatomical changes in the urinary tract
Kidney
•Renal size enlarges by 1 cm, secondary to increased interstitial volume and increased renal vasculature.
•Renal plasma flow rate (RPF) increases early in the first trimester (up to 75% by term).
•Glomerular filtration rate (GFR) increases by 50%, related to an increased cardiac output.
•Renal function and biochemical parameters are affected by changes in RPF and GFR. Creatinine clearance increases, and serum levels of creatinine, urea, and urate fall in normal pregnancy (see Table 15.1). Raised GFR causes an increased glucose load at the renal tubules and results in glucose excretion (glycosuria) in most pregnancies. 24-hour protein excretion remains unchanged. Urine output increases.
•Salt and water handling: A reduction in serum sodium causes reduced plasma osmolality. The kidney compensates by increasing renal tubular reabsorption of sodium. Plasma renin activity is increased 10-fold,
and levels of angiotensinogen and angiotensin are increased 5-fold. Osmotic thresholds for antidiuretic hormone (ADH) and thirst decrease.
•Acid–base metabolism Serum bicarbonate is reduced. Increased progesterone stimulates the respiratory center resulting in reduced PCO2.
Bladder
•Bladder displacement occurs (superiorly and anteriorly) due to the enlarging uterus. The bladder becomes hyperemic, and raised estrogen levels cause hyperplasia of muscle and connective tissues.
Bladder pressures can increase over pregnancy (from 8 to 20 cmH2O), with associated rises in absolute and functional urethral length and pressures.
•Lower urinary tract symptoms: Urinary frequency (>7 voids during the day) and nocturia (>1 void at night) increases over the duration of gestation (incidence of 80–90% in third trimester). Urgency and urge
incontinence also increase secondary to pressure effects from the enlarging uterus.
•Stress urinary incontinence occurs in 22%, and increases with parity (pregnancies that result in delivery beyond 28 weeks’ gestation). It is partly caused by placental production of peptide hormones (relaxin), which induces collagen remodeling and consequent softening of tissues of the birth canal. Infant weight, duration of first and second stages of labor (vaginal delivery), and instrumental delivery (ventouse extraction or forceps delivery) increase risks of postpartum (after delivery of the child) stress incontinence.
PHYSIOLOGICAL AND ANATOMICAL CHANGES 533
Table 14.1 Biochemistry reference intervals
Substance |
Nonpregnant |
Pregnant |
|
|
Sodium (mmol/L) |
135–145 |
132–141 |
|
|
Urea (mmol/L) |
2.5–6.7 |
2.0–4.2 |
|
|
Urate (µmol/L) |
150–390 |
100–270 |
|
|
Creatinine (µmol/L) |
70–150 |
24–68 |
|
|
Creatinine clearance (mL/min) |
90–110 |
150–200 |
|
|
Bicarbonate (mmol/L) |
24–30 |
20–25 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
534 CHAPTER 14 Urological problems in pregnancy
Urinary tract infection (UTI)
Definition
UTI describes a bacterial infection of the urine with >105 colony forming units (CFU)/mL (or >102 CFU/mL if the patient is systemically unwell).
Incidence
Pregnancy does not alter the incidence of UTI, which remains at 4% for women of reproductive age. However, physiological and anatomical changes associated with pregnancy alter the course of infection, causing an increased risk of recurrent UTI and progression to acute pyelonephritis (up to 28%).
Risk factors
These include previous history of recurrent UTIs and pre-existing vesicoureteric reflux. Physiological changes in pregnancy include hydronephrosis with decreased ureteral peristalsis causing urinary stasis. Up to 75% of pyelonephritis cases occur in the third trimester, when these changes are most prominent.
Pathogenesis
A common causative organism is Escherichia coli. An increased risk of gestational pyelonephritis is associated with E. coli containing the virulence factor Dr adhesin.
Complications
UTI increases the risk of preterm delivery, low fetal birth weight, and maternal anemia.
Screening tests
Midstream urine specimen (MSU)
MSU should be obtained at the first antenatal visit and sent for urinalysis and culture to look for bacteria, protein, and blood. A second MSU investigation is recommended at later visits (week 16) to examine for bacteria, protein, and glucose.
Treatment
All proven episodes of UTI should be treated (asymptomatic or symptomatic), guided by urine culture sensitivities. Antibiotics that are safe to use during pregnancy include penicillins (i.e., ampicillin, amoxicillin, penicillin V) and cephalosporins (i.e., cefaclor, cefalexin, cefotaxime, ceftriaxone, cefuroxime). Nitrofurantoin may be used in first and second trimesters only. See Table 14.2 for antibiotics that are not safe to use.
Repeat urine cultures after treatment to check that bacteria have been eliminated.
Acute pyelonephritis requires hospital admission for intravenous antibiotics (cephalosporin or aminopenicillin) until apyrexial, followed by oral antibiotics for 14 days, and repeated cultures for the duration of pregnancy.
|
|
|
URINARY TRACT INFECTION (UTI) |
535 |
|
|
Table 14.2 Antibiotics to avoid in pregnancy* |
|
|||
|
|
|
|
|
|
|
Trimester |
Antibiotic |
Risk in pregnancy |
|
|
|
|
|
|
|
|
1,2,3 |
Tetracyclines |
Fetal malformation; maternal |
|
||
|
|
|
hepatotoxicity; dental discoloration |
|
|
|
|
Quinolones |
Arthropathy |
|
|
1 |
Trimethoprim |
Teratogenic risk (folate antagonist) |
|
||
2,3 |
Aminoglycosides |
Auditory or vestibular nerve damage |
|
||
3 |
Chloramphenicol |
Neonatal gray syndrome |
|
||
|
|
Sulfonamides |
Neonatal hemolysis; methemoglobinemia |
|
|
|
|
Nitrofurantoin |
Maternal or neonatal hemolysis (if used at |
|
|
|
|
|
term), in subjects with G6PD deficiency |
|
|
|
|
|
|
|
|
* See Krieger JN (1986). Complications and treatment of urinary tract infection during pregnancy. Urol Clin North Am 13:685.